Objective:

To discuss how evolving FDA guidance is reshaping the path from clinical trials to approval in retina drug development.

Approach:

• Panel Discussion: A panel at the Retina Innovation Summit included regulatory experts, drug developers, academic advisors, and investors discussing FDA guidance and its impact on ophthalmic clinical development.

Key Findings:

• The FDA's stance on sham controls in intravitreal injection studies suggests they may not be recommended due to potential bias, as noted by Arthur A. Ciociola.
• A single adequate and well-controlled trial may establish substantial evidence of effectiveness under certain circumstances, according to FDA guidance.
• Emphasis on collecting high-quality data rather than larger data sets is crucial for regulatory success, as highlighted by Snehal Shah.
• Early engagement with the FDA and planning for commercialization before approval are essential for drug developers, as discussed by Adrienne L. Graves.
• Regulatory strategy is now inseparable from scientific strategy in drug development, as agreed upon by the panelists.

Interpretation:

Panelists highlighted the importance of understanding FDA guidance and emphasized the need for high-quality clinical evidence in drug development.

Limitations:

• Panelists did not reach a consensus on the interpretation of the FDA's evolving framework.
• Investors face challenges in evaluating companies due to incomplete clarity from public statements and guidance.

Conclusion:

Engaging with the FDA early and throughout the development process is recommended for drug developers.